The Mediterranean School of Oncology 56 th course

The Mediterranean School of Oncology 56 th course “Breast Cancer: from Epidemiology to Treatment” Tunis, November 14, 2008

The Mediterranean School of Oncology An educational program of: Consorzio Interuniversitario Nazionale per la Bio-Oncologia

A Consortium of 15 Italian Universities 32 Full Professors, 55 Associate Professors Ancona Ferrara Napoli Federico II 95 Scientists Bologna Palermo Foggia Campus Biomedico L’Aquila 15 Cancer Clinics Perugia Catanzaro Chieti-Pescara Milano Roma La Sapienza Messina Teramo 12. 000 sqm laboratories 2 Clinical Trial Offices Tumor Registry & Screening Programs www. cinbo. org

Two classes: 1. Italian residents 2. Foreign students (in English); All courses are accredited for ECM by Ministero della Salute, Italy or/and ESMO

10 600 Courses/year 8 Students/year 500 6 400 4 By December 2007: 47 courses >2500 students 300 2 0 2001 2002 2003 2004 2005 2006 2007 0

ssi a US A d lan Pol Iraq lgiu m Sp ain Ge rm any Egy pt Be Ru el Isr a sni a Bo 75 ua nia Fra nc e Lit h ey Tu rk an Jo rd Ira n y Ita l 1954 78 72 35 30 25 20 15 10 5 Students by country

A large spectrum of cancer-related disciplines is covered, including: Molecular pathology & cancer genetics Onco-hemathology Medical oncology Radiation oncology Epidemiology/ biostatistics & clinical trials Cancer prevention & early diagnosis …. .

Educational program • Postgraduate courses; • Training courses for health professionals not frequently dealing with cancer patients; • Special topics for oncology nurses; • Master classes (residential, 2 -weeks, with practical workshops) (Coming soon)

Scholarships Available to candidates <30 years of age. To apply for a scholarship: • a brief curriculum vitae; • a letter of presentation from an authorised officer at the institute of affiliation. For information: http: //www. mso. cinbo. org/

Diapo avaible a partir du 24 novembre prochaine: http: //www. mso. cinbo. org/

A Consortium of 15 Italian Universities Ancona Bologna Campus Biomedico Catanzaro Chieti-Pescara Ferrara Milano Messina Napoli Federico II Palermo Perugia Foggia Roma La Sapienza L’Aquila Teramo

2008 – Course calendar March 3 -4* Digestive cancers: from epidemiology to management March 28 -29 Assessing and managing toxicities of molecularly targeted agents April 11 -12 Highlights in management of gastrointestinal cancer May 9 -10 Highlights in the management of prostate cancer June 13 -14 Highlights in the management of NSCL cancer July 4 -5 Highlights in the management of breast cancer September 26 -27 Highlights in management of kidney cancer October 16 -18 to be defined October 23 -26 to be defined November 7 -8 to be defined November 28 -29 *Cairo, Egypt Translational oncology: novel agents, approaches and targets

The “Formazione a Distanza in Oncologia” (FADO) Program A MSO/CINBO’s pilot project Consorzio Interuniversitario Nazionale per la Bio-Oncologia

FADO Program Designed to build or enhance professional knowledge, skills, and leadership in oncology and related disciplines through distance/online education & training. Teaching is made via satellite technology.

Target audience 1. Residents in medical oncology; 2. Ph. D. students (Dottorato di Ricerca) in oncology and related disciplines Consorzio Interuniversitario Nazionale per la Bio-Oncologia

FADO - Partners Organization & management: Technologies & services:

The Mediterranean Task Force for Cancer Control (MTCC) A MSO/CINBO’s pilot project Consorzio Interuniversitario Nazionale per la Bio-Oncologia

MTCC “An innovative project to raise awareness about cancer prevention and early detection via satellite technology” • courses • videoconferences; • lectures-seminars-lessons; To provide a forum for “distance learning discussion among CINBO member Universities and selected medical Institutions within the mediterranean area”

Launching Meeting of the Mediterranean Task Force for Cancer Prevention and Early Detection (MTCC) February 2 nd, 2007 Rome, Italy With the participation of delegates from: Albania Algeria Croatia Egypt France Greece Italy Jordan Lebanon Lybia Morocco Palestine Portugal Syria Slovenia Spain Tunisia Turkey

Axel Ullrich Pioneer in signal transduction & cancer research Cloned human insulin gene licensed to Eli Lilly Discovered EGFR, HER 2, FLK-1 etc Architect of targeted therapeutics One of the first scientists at Genentech Responsible for Herceptin – annual sales ca. >$1. 0 BN Discoveries led to SUTENT – projected sales >$1. 0 BN Director of Max Planck Society Founder of SUGEN Inc. NASDAQ listed in 1994 Sold to Pharmacia in 1997 for $670 m